Australia markets close in 4 hours 56 minutes

Allergy Therapeutics plc (AGY.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
13.25-0.25 (-1.85%)
At close: 04:37PM GMT
Currency in GBp

Valuation measures4

Market cap (intra-day) 89.98M
Enterprise value 80.00M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.25
Price/book (mrq)2.34
Enterprise value/revenue 1.10
Enterprise value/EBITDA -10.23

Trading information

Stock price history

Beta (5Y monthly) 1.00
52-week change 3-61.43%
S&P500 52-week change 3-16.16%
52-week high 336.00
52-week low 312.50
50-day moving average 316.12
200-day moving average 319.94

Share statistics

Avg vol (3-month) 359.62k
Avg vol (10-day) 3113.51k
Shares outstanding 5679.11M
Implied shares outstanding 6N/A
Float 8115.75M
% held by insiders 184.79%
% held by institutions 16.52%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 June 2022
Most-recent quarter (mrq)30 June 2022

Profitability

Profit margin -18.93%
Operating margin (ttm)-17.00%

Management effectiveness

Return on assets (ttm)-9.57%
Return on equity (ttm)-31.69%

Income statement

Revenue (ttm)72.77M
Revenue per share (ttm)0.11
Quarterly revenue growth (yoy)-20.60%
Gross profit (ttm)49.51M
EBITDA -8.21M
Net income avi to common (ttm)-13.78M
Diluted EPS (ttm)-0.80
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)20.52M
Total cash per share (mrq)0.03
Total debt (mrq)10.53M
Total debt/equity (mrq)27.42
Current ratio (mrq)2.38
Book value per share (mrq)0.06

Cash flow statement

Operating cash flow (ttm)-14.37M
Levered free cash flow (ttm)-11.7M